Holobiome, a cutting-edge biotech company, is poised to revolutionize the microbiome industry with its innovative approach to gut-brain axis research. Led by the visionary Phil Strandwitz, Holobiome’s unique platforms, strategic partnerships, and robust intellectual property portfolio position it as a leader in the burgeoning microbiome market. Here, we are outlining the reasons behind investing in Holobiome.

Founder Expertise and Vision

Phil Strandwitz, the CEO and co-founder of Holobiome, brings unparalleled expertise to the company. With a PhD in Biology from Northeastern University, Phil has dedicated his career to exploring the microbiome and the gut-brain axis, a field that holds immense potential for treating neurological conditions. His co-founder, Kim Lewis, a distinguished professor at Northeastern University, further strengthens the company’s scientific foundation, as well as Mike La Fleur who is simultaneously spearheading Arietis Tx, developing first-in-class small molecule antibiotics.

The advisory board is made up of world-class microbiome scientists, such as Jack Gilbert (UCSD), Elaine Hsiao (UCLA), George Church (Harvard Medical School), and Eran Segal (Weizmann Institute).

This leadership team is not only knowledgeable but extremely also passionate about pushing the boundaries of microbiome science.

Market Potential

The microbiome market is experiencing unprecedented growth, driven by increasing consumer awareness and scientific advancements. Valued at $57 billion in 2022, the global consumer probiotics market is projected to grow at a CAGR of 8.1% from 2022 to 2027. Beyond this, the microbiome therapeutics market has seen a first wave around 2016/2017, with many challenges and hurdles. We now believe that with new insights and progressed scientific evidence, market growth is fueled by the expanding applications of microbiome research in healthcare, including diagnostics, therapeutics, and personalized medicine. Holobiome is well-positioned to capitalize on this market trend, offering innovative solutions that address significant unmet needs in the gut-brain axis domain.

Innovative Approach and Execution

Holobiome’s groundbreaking research into the gut-brain axis sets it apart in the microbiome field. The company utilizes advanced tools and platforms — such as its Microbiome Vault, one of the largest human gut strain libraries in the world — to study and identify specific gut bacteria that play critical roles in brain health and neurological functions. These bacteria, once identified, are cultivated and developed into next-generation probiotics and therapeutic interventions aimed at treating mental health disorders, neurodegenerative diseases, and other conditions linked to gut-brain communication. By focusing on the microbiota-gut-brain axis, Holobiome is pioneering a novel approach that could reshape how we understand and treat a variety of complex health issues.

Strategic Partnerships and Traction

Holobiome has established strategic partnerships with major industry players, validating its business model and enhancing its capacity for growth. These collaborations focus on developing prebiotic and probiotic products that support mental well-being and other health areas like painbenefits. These partnerships not only provide financial and strategic support but also accelerate the translation of scientific discoveries into market-ready products. Moreover, Holobiome has built substantial barriers to entry through its proprietary strain library, advanced profiling techniques, and robust intellectual property. The company’s comprehensive approach, which integrates the identification of therapeutic strains with detailed mechanistic studies, creates a strong competitive moat. Holobiome’s unique combination of assets, including its patent-protected technologies and trade secrets, ensures its leadership position in the microbiome market. This competitive edge is further reinforced by the company’s ability to address multiple health conditions through its versatile platform.

Investing in Holobiome aligns perfectly with our mission to support innovative companies with transformative potential. Phil Strandwitz’s expertise, the robust growth of the microbiome market, Holobiome’s strategic execution, and its strong competitive position make it a compelling investment opportunity. We are excited to be part of Holobiome’s journey as it continues to unlock new frontiers in microbiome research and therapy. Holobiome’s visionary approach and strategic partnerships position it to make a significant impact on global health, addressing critical needs in mental health, pain management, and overall well-being.

Investors

We are happy to share the cap table with other mission-aligned investors, including iSelect Fund, Corundum Systems Biology, Satori Neuro, SkyRiver Ventures, Valor Equity Partners, and Astanor.